Fig. 1From: In silico evaluation of some 4-(quinolin-2-yl)pyrimidin-2-amine derivatives as potent V600E-BRAF inhibitors with pharmacokinetics ADMET and drug-likeness predictionsChemical structures of a sorafenib, b dabrafenib, and c vemurafenibBack to article page